ReviewAdvances in experimental medicine and biology2025
The Role of Epigenetic Modifications in Enhancing Bone Marrow Transplantation Efficacy in Cancer.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow transplantation is an important therapeutic modality in the treatment of hematological malignancies and other hematological diseases. It is typically marred by complications like graft-versus-host disease, engraftment failure of donor cells, and recurrence of the original disease. Epigenetic modifications like DNA methylation, histone modification, and noncoding RNAs play a pivotal role in regulating gene expression and cellular function. Current advances in epigenetics studies have heightened the expectation that they have the potential to enhance the efficacy of transplantation by regulating immune response, improving donor cell engraftment, and manipulating the tumor microenvironment. The current chapter discusses the implication of epigenetic modification for the solution of the issues in bone marrow transplantation, with a special focus on how they can impact graft-versus-host disease, hematopoietic reconstitution, and relapse of cancer. By integrating epigenetic therapies and biomarkers into transplant regimens, the possibility exists to improve patient outcomes and advance personalized medicine in oncology.
Indexed as
Identifiers
40522590What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.